CR9626A - Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato - Google Patents

Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato

Info

Publication number
CR9626A
CR9626A CR9626A CR9626A CR9626A CR 9626 A CR9626 A CR 9626A CR 9626 A CR9626 A CR 9626A CR 9626 A CR9626 A CR 9626A CR 9626 A CR9626 A CR 9626A
Authority
CR
Costa Rica
Prior art keywords
oral
succinate
desmetilvenlafaxin
dosage
ways
Prior art date
Application number
CR9626A
Other languages
English (en)
Inventor
Syed Shah
Mahdi Fawzi
Christopher Richard Diorio
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR9626A publication Critical patent/CR9626A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe una forma de dosificacion unitaria altamente biodisponible, oral de O-desmetilvenlafaxina succinato (DVS) que tiene una sostenida durante multiples horas para proporcionar una liberacion total de mas de alrededor de 85% dentro de aproximadamente 12 a aproximadamente 14 horas; en una modalidad, la composicion DVS superbiodisponible tiene una liberacion retardada de alrededor de 2 horas y una liberacion total de mas de alrededor de 95% durante 12 a aproximadamente 14 horas; tambien se describe el uso de la formulacion para tratar depresion y reducir efectos secundarios gastrointestinales de O-desmetilvenlafaxina (ODV).
CR9626A 2005-07-15 2007-12-20 Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato CR9626A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69962305P 2005-07-15 2005-07-15

Publications (1)

Publication Number Publication Date
CR9626A true CR9626A (es) 2008-04-10

Family

ID=37669348

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9626A CR9626A (es) 2005-07-15 2007-12-20 Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato

Country Status (20)

Country Link
US (1) US20070014859A1 (es)
EP (1) EP1904040A2 (es)
JP (1) JP2009501233A (es)
KR (1) KR20080025405A (es)
CN (1) CN101247791A (es)
AR (1) AR054833A1 (es)
AU (1) AU2006270315A1 (es)
BR (1) BRPI0613484A2 (es)
CA (1) CA2612960A1 (es)
CR (1) CR9626A (es)
EC (1) ECSP088106A (es)
GT (1) GT200600307A (es)
IL (1) IL188313A0 (es)
MX (1) MX2008000666A (es)
NO (1) NO20080088L (es)
PE (1) PE20070192A1 (es)
RU (1) RU2007148195A (es)
SV (1) SV2008002612A (es)
TW (1) TW200740427A (es)
WO (1) WO2007011619A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108421044A (zh) 2005-02-03 2018-08-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
MX2007012167A (es) * 2005-03-31 2007-11-22 Wyeth Corp Producto de combinacion de o-desmetilvenlafaxina y bazedoxifeno, y usos del mismo.
US20080175873A1 (en) * 2005-06-02 2008-07-24 Biovail Laboratories International S.R.L. Modified release composition of at least one form of venlafaxine
BRPI0618042A2 (pt) 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
JP2009518407A (ja) 2005-12-05 2009-05-07 ワイス 置換１−（２−アミノ−１−フェニル−エチル）−シクロヘキサノールのエナンチオマーを選択的に合成するための方法
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
US20100210719A1 (en) * 2007-07-12 2010-08-19 Dr. Reddy's Laboratories Ltd. O-desmethylvenlafaxine
US20100330172A1 (en) * 2007-10-16 2010-12-30 Alphapharm Pty Ltd Controlled-release pharmaceutical formulation
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
BRPI0722303A2 (pt) * 2007-12-10 2014-04-22 Wyeth Llc O-desmatil-venlafaxina para tratar transtorno depressivo maior
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
CN101716168B (zh) * 2008-10-09 2014-09-17 北京德众万全医药科技有限公司 一种含有去甲文拉法新的盐的药物组合物及其制备方法
EP2191822A1 (en) * 2008-11-26 2010-06-02 LEK Pharmaceuticals d.d. Controlled release pharmaceutical compositions comprising O-desmethyl-venlafaxine
IL264349B2 (en) 2009-04-06 2024-01-01 Wyeth Llc Regimen comprising neratinib for the treatment of cancer
NZ599762A (en) 2009-11-09 2014-07-25 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
CA2792352C (en) 2010-03-31 2015-06-23 Wockhardt Limited Modified release dosage form comprising desvenlafaxine or salts thereof
CN102085197B (zh) * 2010-12-14 2013-08-14 北京万生药业有限责任公司 一种文拉法辛缓释制剂及其制备方法
WO2012140577A1 (en) 2011-04-12 2012-10-18 Lupin Limited Modified release pharmaceutical compositions of desvenlafaxine
CN111008356B (zh) * 2019-11-13 2023-06-16 成都理工大学 一种基于WTSVD算法扣除背景的γ能谱集分析方法
CN114288273B (zh) * 2022-02-11 2022-10-18 桂林华信制药有限公司 一种盐酸文拉法辛缓释胶囊及其生产工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
AU5738700A (en) * 1999-06-15 2001-01-02 American Home Products Corporation Enantiomers of o-desmethyl venlafaxine
AR021347A1 (es) * 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
US20030191347A1 (en) * 2002-03-28 2003-10-09 Rolf Keltjens Venlafaxine base
US6703044B1 (en) * 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations
PT1473030E (pt) * 2003-05-02 2007-01-31 Dexcel Ltd Formulação para um comprimido de libertação prolongada de venlafaxina
CN1917860A (zh) * 2004-02-06 2007-02-21 惠氏公司 多颗粒o－去甲基文拉法辛盐及其用途
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology

Also Published As

Publication number Publication date
WO2007011619A2 (en) 2007-01-25
ECSP088106A (es) 2008-02-20
EP1904040A2 (en) 2008-04-02
JP2009501233A (ja) 2009-01-15
IL188313A0 (en) 2008-04-13
KR20080025405A (ko) 2008-03-20
AU2006270315A1 (en) 2007-01-25
WO2007011619A3 (en) 2007-06-21
BRPI0613484A2 (pt) 2016-11-16
US20070014859A1 (en) 2007-01-18
TW200740427A (en) 2007-11-01
AR054833A1 (es) 2007-07-18
CN101247791A (zh) 2008-08-20
SV2008002612A (es) 2008-08-29
CA2612960A1 (en) 2007-01-25
MX2008000666A (es) 2008-03-13
RU2007148195A (ru) 2009-08-20
NO20080088L (no) 2008-04-02
GT200600307A (es) 2008-04-24
PE20070192A1 (es) 2007-03-16

Similar Documents

Publication Publication Date Title
ECSP088106A (es) Formas de dosificación de liberación retardada oral altamente biodisponible del succinato de o-desmetilvenlafaxina
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ES2525320T3 (es) Composiciones de calentamiento y sistemas para su descarga
ES2540751T3 (es) Composición para mejorar la función sexual masculina que contiene extracto de baya de ginseng
ES2602986T3 (es) Nuevas composiciones cosméticas y/o farmacológicas y sus aplicaciones
MX2007005521A (es) Formulaciones estables de peptidos insulinotropicos.
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
CR20120605A (es) Formulación tópica para un inhibidor de jak
CL2010000516A1 (es) Composicion fungicida sin solvente que comprende estrobirulina insoluble en agua dispersado a traves del material portador en forma nano-dispersa teniendo un diametro pico de la forma nano-dispersa menor a 1000 nm; proceso para preparar dicha composicion; uso de dicha composicion para tratar una infestacion (divisional de la sol. 2030-07).
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
CL2008000896A1 (es) Composicion que mantiene el cuidado bucal periodico que comprende un aminoacido basico; uso en el tratamiento terapeutico de la superficie bucal.
CL2008000893A1 (es) Composición para el cuidado bucal que comprende una cantidad efectiva de un aminoácido básico y un agente antibacteriano; uso en el tratamiento antibacteriano de la cavidad bucal.
UY30440A1 (es) Nuevos compuestos
BRPI0606318A2 (pt) composto, composição, e, uso de um composto
AR068369A1 (es) Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"
ES2478264T3 (es) Glicerosomas y uso de estos en preparaciones farmacéuticas y cosméticas para aplicación tópica
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
ES2422556T3 (es) Tratamiento de hepatitis vírica
CY1113449T1 (el) Αντι-ιικες συνθεσεις που περιλαμβανουν γερανιολη και καρβονη
CO6290631A2 (es) Composición oral que contiene amino ácidos y un agente blanqueador
CR7583A (es) Nueva sal formiato de o-desmetil venlafaxina
AR070356A1 (es) Producto para cuidado oral y metodos de uso del mismo
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
CL2008001024A1 (es) Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades cardiovasculares, parkinson, enfermedades inflamatorias, esclerosis multiple, cancer, entre otras
AR109263A2 (es) Composición que comprende moxidectina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)